Sharon Bio-Medicine Ltd. Sharon Bio-Medicine Limited is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and commercialization of pharmaceutical products. The Company operates in three segments, which include Active Pharma Ingredients (API's), Formulations and Toxicology. The Company offers various Active Pharmaceutical Ingredients, including Ketoconazole, Trimetazidine Di HCI, Glimepiride, Eperisone HCI, Memantine HCI, Telmisartan, Nifedipine, Aripiprazole and Atomoxetine HCI. The Company offers various intermediate products, including Cis Bromo Benzoate, N-Acetyl-4(4-Hydroxy Phenyl) Piperazine, Cis Tosylate and Tri Ethyl Benzyl Ammonium Chloride. The Company also offers various services, including preclinical toxicology on small animals, chemical process development and scale up, formulation development, analytical method development, drug master file (DMF) and dossier preparation, and commercial manufacturing of intermediates, actives and finished dosages.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.